Cargando…

CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil

Triple-negative breast cancer (TNBC) is known as the most intricate and hard-to-treat subtype of breast cancer. TNBC cells do not express the well-known estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) expressed by other breast cancer subtypes. This pheno...

Descripción completa

Detalles Bibliográficos
Autores principales: Nasiri, Fatemeh, Kazemi, Mehrasa, Mirarefin, Seyed Mohamad Javad, Mahboubi Kancha, Maral, Ahmadi Najafabadi, Milad, Salem, Faeze, Dashti Shokoohi, Setareh, Evazi Bakhshi, Sahar, Safarzadeh Kozani, Pouya, Safarzadeh Kozani, Pooria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722775/
https://www.ncbi.nlm.nih.gov/pubmed/36483567
http://dx.doi.org/10.3389/fimmu.2022.1018786
_version_ 1784844030492803072
author Nasiri, Fatemeh
Kazemi, Mehrasa
Mirarefin, Seyed Mohamad Javad
Mahboubi Kancha, Maral
Ahmadi Najafabadi, Milad
Salem, Faeze
Dashti Shokoohi, Setareh
Evazi Bakhshi, Sahar
Safarzadeh Kozani, Pouya
Safarzadeh Kozani, Pooria
author_facet Nasiri, Fatemeh
Kazemi, Mehrasa
Mirarefin, Seyed Mohamad Javad
Mahboubi Kancha, Maral
Ahmadi Najafabadi, Milad
Salem, Faeze
Dashti Shokoohi, Setareh
Evazi Bakhshi, Sahar
Safarzadeh Kozani, Pouya
Safarzadeh Kozani, Pooria
author_sort Nasiri, Fatemeh
collection PubMed
description Triple-negative breast cancer (TNBC) is known as the most intricate and hard-to-treat subtype of breast cancer. TNBC cells do not express the well-known estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) expressed by other breast cancer subtypes. This phenomenon leaves no room for novel treatment approaches including endocrine and HER2-specific antibody therapies. To date, surgery, radiotherapy, and systemic chemotherapy remain the principal therapy options for TNBC treatment. However, in numerous cases, these approaches either result in minimal clinical benefit or are nonfunctional, resulting in disease recurrence and poor prognosis. Nowadays, chimeric antigen receptor T cell (CAR-T) therapy is becoming more established as an option for the treatment of various types of hematologic malignancies. CAR-Ts are genetically engineered T lymphocytes that employ the body’s immune system mechanisms to selectively recognize cancer cells expressing tumor-associated antigens (TAAs) of interest and efficiently eliminate them. However, despite the clinical triumph of CAR-T therapy in hematologic neoplasms, CAR-T therapy of solid tumors, including TNBC, has been much more challenging. In this review, we will discuss the success of CAR-T therapy in hematological neoplasms and its caveats in solid tumors, and then we summarize the potential CAR-T targetable TAAs in TNBC studied in different investigational stages.
format Online
Article
Text
id pubmed-9722775
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97227752022-12-07 CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil Nasiri, Fatemeh Kazemi, Mehrasa Mirarefin, Seyed Mohamad Javad Mahboubi Kancha, Maral Ahmadi Najafabadi, Milad Salem, Faeze Dashti Shokoohi, Setareh Evazi Bakhshi, Sahar Safarzadeh Kozani, Pouya Safarzadeh Kozani, Pooria Front Immunol Immunology Triple-negative breast cancer (TNBC) is known as the most intricate and hard-to-treat subtype of breast cancer. TNBC cells do not express the well-known estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) expressed by other breast cancer subtypes. This phenomenon leaves no room for novel treatment approaches including endocrine and HER2-specific antibody therapies. To date, surgery, radiotherapy, and systemic chemotherapy remain the principal therapy options for TNBC treatment. However, in numerous cases, these approaches either result in minimal clinical benefit or are nonfunctional, resulting in disease recurrence and poor prognosis. Nowadays, chimeric antigen receptor T cell (CAR-T) therapy is becoming more established as an option for the treatment of various types of hematologic malignancies. CAR-Ts are genetically engineered T lymphocytes that employ the body’s immune system mechanisms to selectively recognize cancer cells expressing tumor-associated antigens (TAAs) of interest and efficiently eliminate them. However, despite the clinical triumph of CAR-T therapy in hematologic neoplasms, CAR-T therapy of solid tumors, including TNBC, has been much more challenging. In this review, we will discuss the success of CAR-T therapy in hematological neoplasms and its caveats in solid tumors, and then we summarize the potential CAR-T targetable TAAs in TNBC studied in different investigational stages. Frontiers Media S.A. 2022-11-22 /pmc/articles/PMC9722775/ /pubmed/36483567 http://dx.doi.org/10.3389/fimmu.2022.1018786 Text en Copyright © 2022 Nasiri, Kazemi, Mirarefin, Mahboubi Kancha, Ahmadi Najafabadi, Salem, Dashti Shokoohi, Evazi Bakhshi, Safarzadeh Kozani and Safarzadeh Kozani https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Nasiri, Fatemeh
Kazemi, Mehrasa
Mirarefin, Seyed Mohamad Javad
Mahboubi Kancha, Maral
Ahmadi Najafabadi, Milad
Salem, Faeze
Dashti Shokoohi, Setareh
Evazi Bakhshi, Sahar
Safarzadeh Kozani, Pouya
Safarzadeh Kozani, Pooria
CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil
title CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil
title_full CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil
title_fullStr CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil
title_full_unstemmed CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil
title_short CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil
title_sort car-t cell therapy in triple-negative breast cancer: hunting the invisible devil
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722775/
https://www.ncbi.nlm.nih.gov/pubmed/36483567
http://dx.doi.org/10.3389/fimmu.2022.1018786
work_keys_str_mv AT nasirifatemeh cartcelltherapyintriplenegativebreastcancerhuntingtheinvisibledevil
AT kazemimehrasa cartcelltherapyintriplenegativebreastcancerhuntingtheinvisibledevil
AT mirarefinseyedmohamadjavad cartcelltherapyintriplenegativebreastcancerhuntingtheinvisibledevil
AT mahboubikanchamaral cartcelltherapyintriplenegativebreastcancerhuntingtheinvisibledevil
AT ahmadinajafabadimilad cartcelltherapyintriplenegativebreastcancerhuntingtheinvisibledevil
AT salemfaeze cartcelltherapyintriplenegativebreastcancerhuntingtheinvisibledevil
AT dashtishokoohisetareh cartcelltherapyintriplenegativebreastcancerhuntingtheinvisibledevil
AT evazibakhshisahar cartcelltherapyintriplenegativebreastcancerhuntingtheinvisibledevil
AT safarzadehkozanipouya cartcelltherapyintriplenegativebreastcancerhuntingtheinvisibledevil
AT safarzadehkozanipooria cartcelltherapyintriplenegativebreastcancerhuntingtheinvisibledevil